Soleno Therapeutics is breathing easier with a report from Acadia Pharmaceuticals that its candidate to treat hyperphagia in patients with Prader-Willi Syndrome has come up short in a phase 3 trial and has been scrapped by the company. More: Acadia
read moreExcitement around Fujifilm Biotechnologies’ massive new cell culture facility in Holly Springs, North Carolina, has been growing steadily since 2021, prompting a beefed-up investment from the company last April and a string of high-profile manufacturing contracts this year. Now, the
read moreAs drugmakers are turning away from England, Eli Lilly CEO David Ricks has joined the chorus, calling it “probably the worst country in Europe” for drug pricing and adding that England is “not an attractive environment for investment.” More: Big Pharma's
read moreIndian generics makers have inked partnerships with the Gates Foundation, the Clinton Health Access Initiative and other groups to help roll out cheaper versions of Gilead’s Yeztugo in certain low- and middle-income countries. More: Generics makers to sell Gilead's Yeztugo
read more
EU phase 3 data shows major gains in dialysis access performance More: Xeltis prepares for commercial launch after strong aXess trial results Source: News
read more
Acella and Neuvosyn report positive results for investigational DTE therapy More: North Star shows promise in phase 2 thyroid trial Source: News
read more© 1994 - 2025 B.M. Pharmaceuticals